Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18-45
SponsorBaylor College of Medicine

About this trial

An experimental hookworm infection model is being developed to provide early proof-of-concept that a hookworm vaccine targeting the blood-feeding pathway of adult hookworms is feasible and efficacious. The proposed model consists of vaccinating healthy, hookworm-naïve adults with a candidate hookworm vaccine, followed by challenging them with the investigational product, Necator americanus Larval Inoculum to assess the effect of vaccination on infection. The first proposed study will be a feasibility study that will consist of administering different doses of the Necator americanus Larval Inoculum to healthy adult volunteers to determine the optimal dose (i.e., number of infectious larvae) that is safe, well-tolerated and results in consistent infection.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Males or females between 18 and 45 years, inclusive.

Good general health as determined by means of the screening procedure.

Available for the duration of the trial (6 months).

Willingness to participate in the study as evidenced by signing the informed consent document.

Disqualifiers

Pregnancy as determined by a positive urine human choriogonadotropin (hCG) (if female).

Participant unwilling to use reliable contraception methods while participating in the study (if female and not surgically sterile, abstinent or at least 2 years post-menopausal).

Currently lactating and breast-feeding (if female).

Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, rheumatologic, autoimmune, diabetes, or renal disease by history, physical examination, and/or laboratory studies.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Necator americanus Hookworm Larvae

    Biological/Vaccine

    Infectious larvae of the human hookworm Necator americanus

Treatment groups

35 Participants
are divided into 3 treatment groups
Group A: Cohort 1 (25 Necator americanus Hookworm Larvae)Experimental treatment 1 intervention
Group B: Cohort 2 (50 Necator americanus Hookworm Larvae)Experimental treatment 1 intervention
Group C: Cohort 3 (75 Necator americanus Hookworm Larvae)Experimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Study product-related adverse events

Frequency of study product-related adverse events, graded by severity, for different doses of N. americanus Larval Inoculum.

Time frame
Up to 6 months after dosing

Secondary outcomes

1

Fecal egg counts

To determine the dose of N. americanus Larval Inoculum that generates the highest fecal egg counts, measured by fecal microscopy.

Time frame
Up to Study Day 101
2

Number of adult hookworms in feces post-treatment

To compare the N. americanus Larval Inoculum dose received with the number of adult worms present in the gut, as determined by capsule endoscopy.

Time frame
Study Days 87-101

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.